First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50% - Archive ouverte HAL Access content directly
Journal Articles Future Oncology Year : 2021

First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%

(1) , (2, 3) , (4) , (5, 6, 7) , (8, 9) , (10) , (11) , (12) , (13) , (14) , (2) , (1) , (15)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Renaud Descourt
Charles Ricordel

Abstract

Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without EGFR mutations or ALK rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. Clinical trial number: EudraCT (2020-002626-86); ClinicalTrials.gov ( NCT04547504 ).
Not file

Dates and versions

hal-03526346 , version 1 (14-01-2022)

Identifiers

Cite

Renaud Descourt, Christos Chouaid, Maurice Pérol, Benjamin Besse, Laurent Greillier, et al.. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%. Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩. ⟨hal-03526346⟩
26 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More